Clinical trial
Graft-versus-host Disease Prophylaxis With Combination of Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies (PTBCy)
NCT04943757 is registered in ClinicalTrials.gov with St. Petersburg State Pavlov Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Graft-versus-host Disease Prophylaxis With Combination of Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies (PTBCy)
- Lead sponsor
- St. Petersburg State Pavlov Medical University
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 21, 2021
- Completion date
- May 30, 2024
- Enrollment
- 50 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic myeloid leukemia, myelodysplastic syndromes, myeloid leukemia, acute, myeloproliferative neoplasm